{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:04:55Z","timestamp":1772719495285,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40261-018-0635-3","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T06:43:26Z","timestamp":1521614606000},"page":"527-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial"],"prefix":"10.1007","volume":"38","author":[{"given":"Ruth","family":"Pettengell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9015","authenticated-orcid":false,"given":"Anton","family":"Egorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Sivcheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"key":"635_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2147\/OTT.S34055","volume":"7","author":"S Volpetti","year":"2014","unstructured":"Volpetti S, Zaja F, Fanin R. Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Onco Targets Ther. 2014;7:865\u201372.","journal-title":"Onco Targets Ther"},{"issue":"suppl 5","key":"635_CR2","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v83\u201390.","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"635_CR3","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v116\u201325.","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"635_CR4","doi-asserted-by":"crossref","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","volume":"27","author":"U Vitolo","year":"2016","unstructured":"Vitolo U, Seymour JF, Martelli M, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v91\u2013102.","journal-title":"Ann Oncol"},{"key":"635_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.med.59.060906.220345","volume":"59","author":"A Molina","year":"2008","unstructured":"Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin\u2019s lymphoma. Annu Rev Med. 2008;59:237\u201350.","journal-title":"Annu Rev Med"},{"issue":"12","key":"635_CR6","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2009.24.5860","volume":"28","author":"JF Larouche","year":"2010","unstructured":"Larouche JF, Berger F, Chassagne-Clement C, et al. Lymphoma recurrence 5\u00a0years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol. 2010;28(12):2094\u2013100.","journal-title":"J Clin Oncol"},{"issue":"8","key":"635_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12032-016-0801-5","volume":"33","author":"I Fanous","year":"2016","unstructured":"Fanous I, Dillon P. Cancer treatment-related cardiac toxicity: prevention, assessment and management. Med Oncol. 2016;33(8):84.","journal-title":"Med Oncol"},{"issue":"11","key":"635_CR8","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869\u201379.","journal-title":"Cancer"},{"key":"635_CR9","unstructured":"Janssen-Cilag. Imbruvica: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003791\/WC500177775.pdf . Accessed 7 Feb 2018."},{"key":"635_CR10","unstructured":"Gilead Sciences. Zydelig: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003843\/WC500175377.pdf . Accessed 7 Feb 2018."},{"key":"635_CR11","unstructured":"CTI Life Sciences Limited. Pixuvri: summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002055\/WC500127968.pdf . Accessed 10 July 2017."},{"issue":"6","key":"635_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/ejh.12768","volume":"97","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Corradini P, Martelli M, et al. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. Eur J Haematol. 2016;97(6):554\u201361.","journal-title":"Eur J Haematol"},{"issue":"9","key":"635_CR13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/15384047.2015.1070979","volume":"16","author":"N Beeharry","year":"2015","unstructured":"Beeharry N, Di Rora AG, Smith MR, Yen TJ. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Cancer Biol Ther. 2015;16(9):1397\u2013406.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"635_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1124\/jpet.112.200568","volume":"344","author":"E Salvatorelli","year":"2013","unstructured":"Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther. 2013;344(2):467\u201378.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"635_CR15","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","volume":"13","author":"R Pettengell","year":"2012","unstructured":"Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012;13(7):696\u2013706.","journal-title":"Lancet Oncol"},{"issue":"5","key":"635_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.14101","volume":"174","author":"R Pettengell","year":"2016","unstructured":"Pettengell R, Sebban C, Zinzani PL, et al. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. Br J Haematol. 2016;174(5):692\u20139.","journal-title":"Br J Haematol"},{"issue":"8","key":"635_CR17","first-page":"888","volume":"88","author":"P Borchmann","year":"2003","unstructured":"Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin\u2019s lymphomas. Haematologica. 2003;88(8):888\u201394.","journal-title":"Haematologica"},{"issue":"16","key":"635_CR18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s40265-016-0650-8","volume":"76","author":"GM Keating","year":"2016","unstructured":"Keating GM. Pixantrone: a review in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. Drugs. 2016;76(16):1579\u201386.","journal-title":"Drugs"},{"issue":"3","key":"635_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000458147","volume":"62","author":"L Appio","year":"2017","unstructured":"Appio L, Landoni C, La Targia M, et al. Single-agent pixantrone as a bridge to autologous stem cell transplantation in a patient with refractory diffuse large B-cell lymphoma. Chemotherapy. 2017;62(3):187\u201391.","journal-title":"Chemotherapy"},{"issue":"4","key":"635_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000465511","volume":"137","author":"F Malaspina","year":"2017","unstructured":"Malaspina F, Pellegrini C, Casadei B, Argnani L, Zinzani PL. Impressive response to pixantrone after allogeneic transplant in a multiple relapsed diffuse large B-cell lymphoma. Acta Haematol. 2017;137(4):191\u20134.","journal-title":"Acta Haematol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0635-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T20:50:20Z","timestamp":1604004620000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0635-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["635"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0635-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"21 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RP has received honoraria from CTI and Servier. LS has received research funding from CTI as a trial investigator. JS is an employee of CTI. AE is an employee of Servier. BC declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the responsible institutional research committee of each center involved and with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was funded by Servier and CTI. Article processing charges were funded by Servier.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Ruth Pettengell, Bertrand Coiffier and Jack Singer contributed to study design, enrolled patients, and read and approved drafts. Lilia Sivcheva enrolled patients and provided the case report and reviewed and approved the manuscript. Anton Egorov performed the analysis of the PIX301 clinical study report for the scope of this publication and read and provided comments to successive drafts and approved the final version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}